1. Novel Cyclic Endomorphin Analogues with Multiple Modifications and Oligoarginine Vector Exhibit Potent Antinociception with Reduced Opioid-like Side Effects
- Author
-
Si-Yu Wang, Xiao-fang Wang, Meng-meng Wang, Wen-jiao Yang, Yao Zhang, Ya-Nan Zhao, Yu-zhe Zhang, Chang-Lin Wang, Ning Gu, and Feng-tong Han
- Subjects
Pain ,Motor Activity ,Pharmacology ,Mice ,chemistry.chemical_compound ,Drug Discovery ,medicine ,Animals ,Gastrointestinal Transit ,Acute pain ,Analgesics ,Brain ,Motor impairment ,Inflammatory pain ,Conditioned place preference ,Analgesics, Opioid ,Nociception ,chemistry ,Opioid ,Lipophilicity ,Conditioning, Operant ,Molecular Medicine ,Endorphins ,Peptides ,Endomorphin ,medicine.drug - Abstract
Endomorphins (EMs) are potent pharmaceuticals for the treatment of pain. Herein, we investigated several novel EM analogues with multiple modifications and oligoarginine conjugation. Our results showed that analogues 1-6 behaved as potent μ-opioid agonists and enhanced stability and lipophilicity. Analogues 5 and 6 administered centrally and peripherally induced significant and prolonged antinociceptive effects in acute pain. Both analogues also produced long-acting antiallodynic effects against neuropathic and inflammatory pain. Furthermore, they showed a reduced acute antinociceptive tolerance. Analogue 6 decreased the extent of chronic antinociceptive tolerance, and analogue 5 exhibited no tolerance at the supraspinal level. Particularly, they displayed nontolerance-forming antinociception at the peripheral level. In addition, analogues 5 and 6 exhibited reduced or no opioid-like side effects on gastrointestinal transit, conditioned place preference (CPP), and motor impairment. The present investigation established that multiple modifications and oligoarginine-vector conjugation of EMs would be helpful in developing novel analgesics with fewer side effects.
- Published
- 2021